Herraets, Ingrid J. T.
Bakers, Jaap N. E.
van Eijk, Ruben P. A.
Goedee, H. Stephan
van der Pol, W. Ludo
van den Berg, Leonard H.
Funding for this research was provided by:
Takeda (BT14-23778/IIR-NLD-BXLT-001965)
Article History
Received: 13 June 2019
Revised: 12 July 2019
Accepted: 13 July 2019
First Online: 19 July 2019
Compliance with ethical standards
:
: IH, JB, RE—these authors declare that they have no conflict of interest. SG—receives research support from the Prinses Beatrix Spierfonds, and received a travel grant and speaker fee from Shire/Takeda. LP—receives research support from the Prinses Beatrix Spierfonds, and Stichting Spieren voor Spieren. LB—serves on scientific advisory boards for Orion, Biogen, and Cytokinetics; received an educational grant from Baxalta/Takeda; serves on the editorial boards of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration and the Journal of Neurology, Neurosurgery, and Psychiatry; and receives research support from the Prinses Beatrix Spierfonds, Netherlands ALS Foundation, The European Community’s Health Seventh Framework Programme (Grant agreement no. 259867), and The Netherlands Organization for Health Research and Development (Vici Scheme, JPND [SOPHIA, STRENGTH, ALSCare]).
: All the patients gave written informed consent.
: The study protocol was approved by the local medical ethics committee Utrecht (METC Utrecht; file ID NL52642.041.15) and registered in the Eudra-CT (2015-000828-28) and clinicaltrial.gov (NCT02885259) databases and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.